Benzene-1,2-diamine;hydron;dichloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzene-1,2-diamine;hydron;dichloride
• 化学式: C6H10Cl2N2
• 分子量: 181.06
• InChiKey: RIIWUGSYXOBDMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.69
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52
• 氢给体数：
  4
• 氢受体数：
  2

ADMET

毒理性

• 致癌物分类

国际癌症研究机构致癌物：对苯二胺二盐酸

IARC Carcinogenic Agent:ortho-Phenylenediamine dihydrochloride

来源:International Agency for Research on Cancer (IARC)

毒理性

• 致癌物分类

国际癌症研究机构（IARC）致癌物分类：2B组：可能对人类致癌

IARC Carcinogenic Classes:Group 2B: Possibly carcinogenic to humans

来源:International Agency for Research on Cancer (IARC)

毒理性

• 致癌物分类

国际癌症研究机构专著：第123卷：（2020年）一些硝基苯和其他工业化学品

IARC Monographs:Volume 123: (2020) Some Nitrobenzenes and Other Industrial Chemicals

来源:International Agency for Research on Cancer (IARC)

毒理性

• 副作用

职业性肝毒素 - 第二性肝毒素：在职业环境中的毒性效应潜力是基于人类摄入或动物实验的中毒案例。 高铁血红蛋白血症 - 血液中高铁血红蛋白含量增加；该化合物被归类为第二毒性效应 皮肤致敏剂 - 能诱导皮肤过敏反应的制剂。

Occupational hepatotoxin - Secondary hepatotoxins: the potential for toxic effect in the occupational setting is based on cases of poisoning by human ingestion or animal experimentation. Methemoglobinemia - The presence of increased methemoglobin in the blood; the compound is classified as secondary toxic effect Skin Sensitizer - An agent that can induce an allergic reaction in the skin.

来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

毒理性

• 解毒与急救

/SRP:/ 立即急救：确保已经进行了充分的中和。如果患者停止呼吸，请开始人工呼吸，最好使用需求阀复苏器、袋阀面罩装置或口袋面罩，按训练操作。如有必要，执行心肺复苏。立即用缓慢流动的水冲洗受污染的眼睛。不要催吐。如果发生呕吐，让患者前倾或将其置于左侧（如果可能的话，头部向下）以保持呼吸道畅通，防止吸入。保持患者安静，维持正常体温。寻求医疗帮助。 /有机碱/胺类及相关化合物/

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Organic bases/Amines and related compounds/

来源:Hazardous Substances Data Bank (HSDB)

反应信息

• 作为反应物：
  描述：

  布洛芬 、 Benzene-1,2-diamine;hydron;dichloride 以90%的产率得到
  参考文献：
  名称：

  PRITPAL, SINGH;HINGORANI, L. L.;TRIVEDI, G. K.;VORA, JYOTI, INDIAN J. CHEM. B, 29,(1990) N, C. 596-597

  摘要：

  DOI：
• 作为产物：
  描述：

  邻苯二胺 、 盐酸 生成 Benzene-1,2-diamine;hydron;dichloride
  参考文献：
  名称：

  VLASSA, MIRCEA CLUJ-NAPOCA

  摘要：

  DOI：

文献信息

• CONJUGATES FOR THE PREVENTION OR TREATMENT OF NICOTINE ADDICTION
  申请人：BROWN Alan Daniel

  公开号：US20110300174A1

  公开（公告）日：2011-12-08

  The present invention relates in part to nicotine-derived hapten-carrier conjugates of the formula (III): wherein m, n, W, -(spacer)-, X* and Y are as defined in the description. In certain embodiments, said nicotine-derived hapten-carrier conjugates can be used to prepare vaccines for the treatment and/or prevention of nicotine addiction.

  本发明部分涉及公式（III）中尼古丁衍生半抗原载体共轭物： 其中m、n、W、-(spacer)-、X*和Y如描述中所定义。在某些实施例中，所述尼古丁衍生半抗原载体共轭物可用于制备用于治疗和/或预防尼古丁成瘾的疫苗。
• [EN] BENZIMIDAZOLE OR INDOLE AMIDES AS INHIBITORS OF PIN1<br/>[FR] AMIDES DE BENZIMIDAZOLE OU D'INDOLE EN TANT QU'INHIBITEURS DE PIN1
  申请人：PFIZER

  公开号：WO2006040646A1

  公开（公告）日：2006-04-20

  The invention relates to compounds of the formula (1) and to pharmaceutically acceptable salts and solvates thereof, wherein the variables are defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula (1) and to pharmaceutical compositions for treating such disorders that contain the compounds of formula (1). The invention also relates to methods of preparing the compounds of formula (1).

  这项发明涉及公式（1）的化合物，以及其药学上可接受的盐和溶剂化合物，其中变量在此处定义。该发明还涉及通过给予公式（1）的化合物来治疗哺乳动物中的异常细胞生长的方法，以及用于治疗包含公式（1）化合物的这类疾病的药物组合物。该发明还涉及制备公式（1）化合物的方法。
• PYRIDIN-2YL SULFANYL ACID ESTERS AND PROCESS FOR THE PREPARATION THEREOF
  申请人：Sarma Jadab Chandra

  公开号：US20130131350A1

  公开（公告）日：2013-05-23

  The present invention relates to Pyridin-2-yl sulfanyl acid ester compounds having antiinflammatory properties. The present invention particularly relates to novel anti-inflammatory heterocyclic acid esters of Pyridin-2-yl sulfanyl having the structure of general formula 1 which have been screened for their antiinflammatory activity with respect to inhibition of adhesion of neutrophils, isolated from human peripheral blood, onto the surface of human umbilical vein endothelial cells (HU-VEC) as a result of inhibition of the cytokine-stimulated expression of cell adhesion molecule ICAM-1. The compound RS—Z, 3-(Pyridin-2-yl sulfanyl)-propionic acid pentyl ester (structure 1a, R 1 =H, R 2 =H, R 3 =CH2-COOC5H 11 ) was found to be most effective for ICAM-1 and neutrophil adhesion inhibition and was found to effectively alleviate inflammation mediated by excessive leukocyte infiltration leading to inflammatory disorders or like conditions, such as acute lung injury and acute respiratory distress syndrome in mice.

  本发明涉及具有抗炎性能的吡啶-2-基硫醇酸酯化合物。本发明特别涉及吡啶-2-基硫醇的新型抗炎杂环酸酯，其具有通式1的结构，已经针对其抗炎活性进行了筛选，以抑制从人类外周血液中分离出的中性粒细胞粘附到人脐静脉内皮细胞（HU-VEC）表面，结果是通过抑制细胞粘附分子ICAM-1的细胞因子刺激表达来实现。化合物RS—Z，3-(吡啶-2-基硫醇)-丙酸戊酯（结构1a，R1=H，R2=H，R3=CH2-COOC5H11）被发现对ICAM-1和中性粒细胞粘附抑制效果最显著，并且被发现有效缓解由过度白细胞浸润引起的炎症，导致炎症性疾病或类似症状，如小鼠的急性肺损伤和急性呼吸窘迫综合征。
• Heterocycle-substituted Pyridyl Benzothiophenes as Kinase Inhibitors
  申请人：Allergan, Inc.

  公开号：US20160102081A1

  公开（公告）日：2016-04-14

  This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

  这项发明涉及一种具有化学式I的化合物或其药用可接受的盐，其中R1、R2、R3、R4和X如本文所定义。化合物I的用途包括作为受体酪氨酸激酶（RTK）抑制剂，并可用于治疗癌症、血管增生性疾病、纤维化疾病、系膜细胞增生性疾病和代谢性疾病。
• Pyridazinones as antagonists of alpha4 integrins
  申请人：Barbay Kent

  公开号：US20050192279A1

  公开（公告）日：2005-09-01

  The present invention relates to certain novel compounds of Formula (I): methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of integrin mediated disorders.

  本发明涉及某些化合物的新颖结构，其化学式为（I）：制备这些化合物的方法，组合物，中间体及其衍生物以及用于治疗整合素介导的疾病。

表征谱图